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Commentary
Evaluation of the structural and functional 
integrity of the mammary gland (MG), an 
important reproductive tissue/organ, is integral 
to the assessment of develop  mental, reproduc‑
tive, and carcinogenic risk for environ  mental 
chemicals [Organisation for Economic 
Co‑operation and Development (OECD) 
2008; U.S. Environmental Protection Agency 
(EPA) 1991, 1996, 2005a, 2005b]. When 
using a life‑stage–oriented approach to risk 
assessment, it is important to assess early 
develop  mental periods (including in utero 
through puberty), function during reproduc‑
tive life stages, and continued health in later 
life stages.
The evidence for alterations in MG develop‑
ment, lactational function, and cancer risk is 
reviewed by Rudel et al. (2011). Examples of 
hormonally active agents that are associated 
with MG alterations include diethylstilbestrol 
(DES), genistein, atrazine, bisphenol A (BPA), 
dibutyl phthalate, dioxin, methoxy  chlor, 
nonyl  phenol, polybrominated diphenyl ethers 
(PBDEs), and perfluoro  octanoic acid (PFOA).
Animal studies are traditionally used 
in predicting potential toxicity and risk to 
humans. The use of this approach to screen 
environ  mental chemicals for MG toxicity is 
supported by parallels between MG effects 
induced in animal models and alterations in 
human MG health. Examples include altered 
timing of puberty, alterations in lactation (e.g., 
ability to lactate, quality and quantity of milk), 
and induction of mammary/breast cancer.
Standardized study designs or protocols 
(i.e., guidelines) are often used to screen 
chemi  cals for adverse effects related to chemi‑
cal exposures. Examples are those published 
by the U.S. EPA, OECD, and National 
Toxicology Program (NTP). The applica‑
tion and use of these guideline studies gener‑
ally depend on the regulatory agency and its 
applicable legislative mandates for specified 
chemical classes and their anticipated uses or 
potential human exposures. The arsenal of 
study types is relatively consistent across orga‑
nizations and programs, partly because testing 
paradigms are established on accepted bio‑
logical principles and validated experi  mental 
procedures, and partly because of concerted 
efforts to develop and maintain consistency 
(e.g., through the guideline harmonization 
program implemented by the U.S. EPA and 
OECD). Some guidelines include assessment 
of MG end points. Here I charac  terize MG 
assessment in guideline study protocols used 
in chemical testing and identify any informa‑
tion gaps in the testing paradigm. 
Materials and Methods
For this evaluation, I selected published 
U.S. EPA, OECD, and NTP toxicity testing 
guidelines in rodents. These guidelines were 
developed with a rigorous peer‑review process 
and have a long‑standing history of use, inter‑
pretation, and application in data evaluation 
and risk assessment. U.S. EPA and OECD 
guidelines, although “harmonized,” were both 
included here because there are some minor 
but important differences.
I used guidelines available on the 
U.S. EPA, OECD, and NTP web sites (NTP 
2008; OECD 2011; U.S. EPA 2010b) as 
source docu  ments for the analysis of MG 
testing recom  mendations. Because MG is a 
reproductive tissue, guideline studies designed 
to provide some assessment of reproduc‑
tive system structure or function (including 
develop  mental outcomes) have been identi‑
fied (Table 1). They fall into several general 
cate  gories: studies that a) include an assess‑
ment of reproductive function and out‑
come, b) evaluate endocrine‑related effects, 
and c) examine general organ toxicity and 
pathology after less‑than‑lifetime (sub  acute 
or sub  chronic) or after long‑term (chronic or 
lifetime) chemical exposures.
The types of MG assessments in these 
guideline studies include direct measure‑
ments of MG structure or function, as well 
as measure  ments of biomarkers that provide 
surrogate indicators of potential effects on the 
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MG (Table 2). Each guideline protocol was 
examined to ascertain which MG assessments 
are explicitly or implicitly recommended.
Results
Studies including assessments of reproductive 
function and outcome. U.S. EPA, OECD, 
and NTP rodent protocols that include an 
assessment of reproductive function and an 
exami  na  tion of the production and main‑
tenance of offspring also include a lactation 
phase and thus provide some degree of MG 
assessment. Guidelines that include a lactation 
phase are the reproduction/develop  mental 
toxicity screening test (with and without 
a repeated dose toxicity segment) (OECD 
1995, 1996; U.S. EPA 2000b, 2000c), the 
one‑generation reproduction study (OECD 
1983), the two‑generation reproduction 
study (OECD 2001b; U.S. EPA 1998f), the 
develop  mental neuro  toxicity (DNT) study 
(OECD 2007a; U.S. EPA 1998j), and the 
NTP reproductive assessment by continuous 
breeding (RACB) (Chapin and Sloane 1996). 
I also considered the draft OECD extended 
one‑generation reproduction study (OECD 
2010) in this analysis because the protocol has 
been developed as a collaborative harmonized 
effort between the OECD and the U.S. EPA, 
and it is currently under  going public and 
peer‑review processes expected to culminate 
in finali  za  tion. I did not include the pre  natal 
develop  mental toxicity study guideline in this 
list because it specifies termination of the dam 
and fetuses before expected delivery and does 
not include a lactation phase or direct assess‑
ment of MG function in dams or post  natal 
develop  ment in offspring.
Brief descriptions of the selected proto‑
cols follow. The U.S. EPA and OECD proto‑
cols are illustrated in Supplemental Material, 
Figure 1 (doi:10.1289/ehp.1002676). 
•	The	U.S. EPA/OECD reproduction/
develop  mental screening studies are intended 
to generate initial toxicity information 
and prioritize the need for further testing 
of industrial chemicals; they are also used 
in toxicological screening of pesticide inert 
ingredients. These screening protocols include 
a single mating. Pups are maintained only to 
post  natal day (PND) 4, at which time the 
study is terminated; end point assessments 
are limited in number and scope.
•	The	OECD	one-generation	reproduction	
study includes a single mating; however, the 
litters are maintained and evaluated until the 
time of weaning (PND21). This protocol, 
which is sometimes used as a preliminary 
screening or dose range–finding study, does 
not include endocrine end points that were 
added to the U.S. EPA and OECD two‑
generation reproduction study guidelines 
during updating and harmonization efforts 
conducted in the late 1990s.
•	The	U.S. EPA/OECD DNT study includes a 
single mating period, and offspring are main‑
tained throughout the lactation period and 
kept on study until approximately PND70. 
The primary focus of this study is the assess‑
ment of neuro  behavioral develop  ment and 
neuro  pathology of the offspring, rather than 
on the reproductive system, and observations 
of the maternal animals are not extensive.
•	In	the	U.S. EPA/OECD two‑generation 
reproduction study (also called a reproduc‑
tion and fertility effects study), weanling off‑
spring from the first generation are selected 
as parental animals for the second genera‑
tion. Thus, data from two lacta  tion periods 
are typically available. This study includes 
enhanced reproductive, endocrine, and post‑
mortem data that originated from guideline 
harmonization efforts.
•	The	draft	extended	one-generation	reproduc‑
tion study under collaborative develop  ment 
by OECD and U.S. EPA is intended to 
provide an enhanced alternative method for 
develop  mental/reproductive toxicity screen‑
ing that incorporates DNT and develop‑
mental immuno  toxicity testing, assesses 
endocrine end points, and enhances post‑
mortem evaluations, while at the same time 
using fewer animals and using them more 
efficiently than traditional guideline studies.
•   The NTP RACB study is an enhancement 
to a two‑generation reproduction study 
Table 1. U.S. EPA, OECD, and NTP guidelines that assess developmental and reproductive toxicity in mammalian species.
Guideline U.S. EPA OECD NTP
Studies that include assessments of reproductive function and outcome
Prenatal developmental toxicity OPPTS 870.3700 (U.S. EPA 1998e) TG 414 (OECD 2001a) a
One-generation reproduction b,c TG 415 (OECD 1983) b
Reproduction and fertility effects (two-generation reproduction) OPPTS 870.3800 (U.S. EPA 1998f) TG 416 (OECD 2001b) b
RACB b b a
Reproduction/developmental toxicity screening test OPPTS 870.3550 (U.S. EPA 2000a) TG 421 (OECD 1995) b
Combined repeated dose toxicity study with the reproduction/
developmental toxicity screening test
OPPTS 870.3650 (U.S. EPA 2000b) TG 422 (OECD 1996) b
DNT OPPTS 870.6300 (U.S. EPA 1998j) TG 426 (OECD 2007a) b
Endocrine screening and testing studies
Uterotrophic assayd OPPTS 890.1600 (U.S. EPA 2009d) TG 440 (OECD 2007b) b
Hershberger assayd OPPTS 890.1400 (U.S. EPA 2009a) TG 441 (OECD 2009c) b
Juvenile/peripubertal male assayd OPPTS 890.1500b,c (U.S. EPA 2009c) b
Juvenile/peripubertal female assayd OPPTS 890.1450b,c (U.S. EPA 2009b) b
General organ toxicity assessments after less-than-lifetime exposures
14-Day oral toxicity in rodentse b b a
28-Day oral toxicity in rodentse OPPTS 870.3050 (U.S. EPA 2000a) TG 407 (OECD 2005) b
21/28-Day dermal toxicitye b TG 410 (OECD 1981a) b
28-Day inhalation toxicitye b TG 412 (OECD 2009a) b
90-Day oral toxicity in rodentse OPPTS 870.3100 (U.S. EPA 1998a) TG 408 (OECD 1998a) a
90-Day oral toxicity in nonrodentse OPPTS 870.3150 (U.S. EPA 1998b) TG 409 (OECD 1998b) b
90-Day dermal toxicitye OPPTS 870.3250 (U.S. EPA 1998c) TG 411 (OECD 1981b) b
90-Day inhalation toxicitye OPPTS 870.3465 (U.S. EPA 1998d) TG 413 (OECD 2009b) b
General organ toxicity assessments after long-term or lifetime exposures
Chronic toxicitye OPPTS 870.4100 (U.S. EPA 1998g) TG 452 (OECD 2009e) b
Carcinogenicitye OPPTS 870.4200 (U.S. EPA 1998h) GL 451 (OECD 2009d) b
Combined chronic toxicity/carcinogenicitye OPPTS 870.4300 (U.S. EPA 1998i) GL 453 (OECD 2009f) a
Combined chronic toxicity/carcinogenicity testing of respirable fibrous 
particlese
OPPTS 870.8355 (U.S. EPA 2001) b b
Abbreviations: OPPTS, Office of Prevention, Pesticides and Toxic Substances; TG, Test Guideline.
aBased on NTP guidelines available online (NTP 2008); the NTP does not catalog or identify guidelines using a numerical coding system. bNo comparable assay listed on agency/
organiza  tion web site. cU.S. EPA and OECD collaborative effort on guideline development. dEndocrine screening assay. eAlthough not traditionally considered to be a reproductive 
toxicity assay, the protocol contains reproductive system end points that should be considered in a weight-of-evidence evaluation of developmental and reproductive toxicity.Mammary gland assessment in guideline studies
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protocol that is designed around the con‑
duct of targeted study segments or “tasks.” 
Task 1 is a dose range–finding study; task 2 
is a continuous 14‑week breeding segment 
using serial matings to determine fertility 
and reproductive outcome, with early post‑
natal termination of the first sets of litters 
and then maintenance of the final litter to 
the age of weaning (Chapin and Sloane 
1996); task 3 incorporates the use of naive 
females or control males in cross  over mat‑
ings with high‑dose animals to assess pos‑
sible sex‑ and treatment‑related reproductive 
effects; and task 4 initiates the production of 
a second generation.
Overall, none of these study protocols 
focus on end points specific to MG develop‑
ment, health, or successful nursing behaviors. 
However, they all include recommendations 
for regular scheduled clinical observations of 
both parental animals and offspring, includ‑
ing during periods of lactation. In a well‑
conducted toxicology study, such clinical 
observations should be able to detect gross (but 
perhaps not subtle) abnormalities in maternal 
mammary tissue conformity and function, as 
well as disruptions in normal nesting and nurs‑
ing behaviors. Many of the studies also include 
necropsy of the parental animals, which might 
be expected to identify macro  scopic abnormal‑
ities of the mammary tissue; histo  pathological 
evaluation of abnormal reproductive system 
tissues is not specified for the reproduction/
develop  mental toxicity screening test or for 
the DNT study. Compromised health status 
of pups may also provide some indication of 
physical or behavioral alterations to maternal 
lactation. For example, delayed growth (body 
weight) in pups, an absence of evidence of 
milk in the stomach of very young rodent pups 
(which can be visualized externally as a “milk 
spot” or “milk band”), or offspring dehy‑
dration and morbidity may be indicative of 
malnutrition or interrupted nursing behavior.   
There is generally insufficient information to 
determine if the effect is due to physiological 
or behavioral alterations in maternal lactation 
or direct toxicity to the pups that compromises 
their ability to nurse or thrive.
Most of the protocols in this category 
include some assessment of endocrine‑ 
mediated develop  mental or reproductive 
biomarkers that can be informative regard‑
ing disruptions in MG develop  ment or func‑
tion (exceptions being the U.S. EPA/OECD 
develop  mental/reproduction screening tests 
and the OECD one‑generation reproduction 
study). The age of offspring sexual maturation is 
recorded in the U.S. EPA/OECD DNT study, 
and estrous cyclicity is evaluated in the NTP 
RACB study. A number of endocrine‑mediated 
end points are assessed in the two‑generation 
reproduction study: age of sexual maturation, 
ano  genital distance measure  ments (when trig‑
gered by other adverse findings), and estrous 
cyclicity. The draft OECD extended one‑gener‑
ation reproduction study expands upon this list 
by including an assessment of the age at sexual 
maturation, anogenital distance measure  ments 
(in all offspring; i.e., not triggered by other 
adverse findings as in the two‑generation repro‑
duction study), evaluations of nipple/areola 
retention in male pups, and estrous cyclicity.
Studies used in endocrine screening and 
testing. Endocrine screening programs for 
environ  mental toxicants, using a tiered testing 
approach, have been initiated by the U.S. EPA 
and OECD. Tier 1 tests consist of a battery 
of assays designed to efficiently and effectively 
screen chemicals for intera  ctions with the 
estrogen, androgen, or thyroid hormonal sys‑
tems. If a weight‑of‑evidence evalua  tion of the 
results from the Tier 1 assays indicates poten‑
tial inter  action with these hormonal systems, 
then additional, more comprehensive screen‑
ing would be implemented in Tier 2 testing. 
Assays that have been validated for use in 
Tiers 1 and 2 are listed in Table 3. The overall 
endocrine profile for a chemical may provide 
important information regarding the poten‑
tial for MG toxicity or disruption of MG 
develop  ment. However, the evalua  tion of MG 
tissue or function is seldom addressed in the 
endocrine screening protocols. A review of the 
Tier 1 guidelines identified only four in vivo 
mammalian studies, none of which included 
a lactation phase with potential assessment 
of MG function [see Supplemental Material, 
Figure 2 (doi:10.1289/ehp.1002676)]. The 
utero  trophic assay (OECD 2007b; U.S. EPA 
2009d) is designed to screen for (anti)estro‑
genic activity in ovariectomized or immature 
female rats; the Hershberger assay (OECD 
2009c; U.S. EPA 2009a) screens for andro‑
genic activity in castrated peri  pubertal male 
rats; and the male and female pubertal assays 
(U.S. EPA 2009b, 2009c) evaluate (anti)
androgenic plus thyroid activity in male rats 
or estrogenic plus thyroid activity in female 
rats during sexual maturation. Although these 
studies include general clinical and necropsy 
observations, the evaluations do not focus 
on palpation or examination of mammary 
tissue, and histopathology of abnormal mam‑
mary tissue or of mammary tissue from ani‑
mals treated during MG develop  ment is not 
specified. Notably, optional assessments of 
serum levels of reproductive hormones are 
included in the Hershberger and pubertal 
assays; these data are possible biomarkers of 
endocrine disruption that could be indica‑
tive of alterations in MG develop  ment, struc‑
ture, or function. Tier 2 endocrine screening 
includes the two‑  generation reproduction 
study, described above.
Studies examining general organ toxicity 
and pathology. Although studies designed to 
evaluate general organ toxicity and pathology 
do not typically include a lactation phase [see 
Supplemental Material, Figure 3 (doi:10.1289/
ehp.1002676)], they do include clinical and 
postmortem assessments of   reproductive organs.
Less‑than‑lifetime (subacute or sub‑
chronic) chemical exposures. By definition, 
subacute studies are approximately 14 or 
28 days in duration, and subchronic studies 
are 3–6 months in duration. These studies are 
typically used to establish dose levels for subse‑
quent longer‑term studies or to identify target 
organ toxicity. There are NTP guidelines for 
14‑ and 90‑day studies (NTP 2010b) and U.S. 
EPA and OECD guidelines for 28‑ and 90‑day 
studies (OECD 1998a, 2005; U.S. EPA 
1998a, 2000a). These studies are generally con‑
ducted in young adult animals. Abnormalities 
in mammary tissues may be detected in either 
sex by palpation during in‑life clinical observa‑
tions (conducted at least weekly) or may be 
observed at necropsy. Study protocols provide 
lists of organs/tissues for dissection, fixation, 
Table 2. Evaluation of MG structure and function 
in rodent toxicology studies.
Direct structural or functional measurements
Clinical observations, palpationa




Maternal and pup nursing behavior
Pup survival and body weight gainb
Presence of “milk spot” in pups
Measurement of milk composition
Measurements of related biomarkers
Endocrine-sensitive developmental landmarks
Anogenital distance





aAdult assessments. bPup weight gain and survival can 
be surrogate indicators of normal lactation.
Table 3. Endocrine disruptor tiered testing approach 
(U.S. EPA 2010a).
Assay Species
Tier 1 testing assays
Amphibian metamorphosis Frog





Fish short-term reproduction screen Fish
Uterotrophic assay Rat
Hershberger assay Rat
Pubertal male assay Rat
Pubertal female assay Rat




Avian two-generation Japanese quail
Fish life cycle Fish
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sectioning, and microscopic examination and 
specify histopathological evaluation of abnor‑
mal tissues. MG evaluation is not consistently 
recommended across U.S. EPA, OECD, and 
NTP subacute and subchronic guidelines. The 
NTP 14‑day guideline recommends histo‑
pathology of abnormal MG tissue for either 
sex. The U.S. EPA 28‑day guideline (U.S. 
EPA 2000a) does not mention MG assess‑
ment. However, the OECD 28‑day guide‑
line (OECD 2005) includes a list of tissues 
intended to provide indicators for endocrine‑
related effects, specifying evaluation of male 
(but not female) MG tissue, and it states that 
“changes in male mammary glands have not 
been sufficiently documented but this param‑
eter may be very sensitive to substances with 
estrogenic action.” In the 90‑day subchronic 
guidelines, the U.S. EPA and OECD recom‑
mend assessment only of female mammary tis‑
sue, whereas the NTP recom  mends evaluation 
of abnormal tissue in both sexes.
Long‑term (chronic) or lifetime exposures. 
Long‑term studies in rodents are > 6 months 
in duration. The duration of studies that are 
designed to approxi  mate lifetime exposure to 
a chemical and that focus on assessment of 
carcinogenicity is at least 18 months in the 
mouse and 24 months in the rat. In addition 
to regular (at least weekly) clinical observa‑
tions in these studies, macroscopic observations 
are collected at interim and terminal sacrifice, 
and histopathology of MG tissue is routinely 
required, whether or not abnormalities are 
observed in‑life or at necropsy. U.S. EPA and 
OECD protocols (OECD 2009e, 2009f; U.S. 
EPA 1998g, 1998h, 1998i, 2001) specify MG 
histo  pathology only for female rodents, whereas 
NTP protocols do not make a distinction 
between sexes (NTP 2010b). It is in long‑term 
studies that MG cancer is usually identified, 
due partly to a) the extended treatment period, 
b) the statistical power of larger group sizes 
used in these studies (i.e., ≥ 50 rodents/sex/
group, compared with ~ 10–20/sex/group in 
short‑term studies), and c) the focus on histo‑
pathological evaluation, often including rigor‑
ous pathology peer review.
Perinatal exposures. Historically, the 
contribution of early life exposures to toxic‑
ity assessments in subacute, subchronic, and 
chronic studies has not been routinely evalu‑
ated for environ  mental chemicals. Current 
U.S. EPA and OECD guidelines do not specify 
that the animals placed on study be exposed to 
the test chemical during in utero or pre  weaning 
develop  ment; most are placed on study as 
young adults of 5–6 weeks of age. The NTP, 
however, has recently taken an important step 
in this direction by providing detailed informa‑
tion for the application of a peri  natal treatment 
phase in range‑finding, 13‑week, and 2‑year 
studies in rats (NTP 2010a); other species are 
not addressed. In this perinatal study design, 
pregnant dams are exposed to the test sub‑
stance starting at gestation day 6, and exposure 
is continued through to weaning of the litters at 
PND21. Thus, the offspring are exposed to the 
test substance during post  implantation in utero 
develop  ment, during post  natal develop  ment 
via maternal milk, and through direct expo‑
sure (i.e., in treated feed or water or by gavage 
adminis  tration). At weaning, selected offspring 
are assigned to the 13‑week and 2‑year studies 
for continuation of treatment.
Discussion
Table 4 summarizes the extent of MG evalua‑
tion in U.S. EPA, OECD, and NTP guideline 
rodent toxicology studies, focusing on lactation 
assessments in dams and pups; the evaluation 
of develop  mental or reproductive endocrine 
end points that can serve as biomarkers for 
MG disruption; and the examination of mater‑
nal clinical observation, macroscopic pathol‑
ogy, and histopathology data.
In this analysis, I have identified several data 
gaps, issues, and challenges: 
•	Guidelines	that	include	a	reproduction	
phase do not specify that observations on 
maternal or offspring lactation or nursing 
behavior should be recorded.
•	Many	of	the	functional	mammary	end 
points assessed are indirect or non  specific. 
For example, observed treatment‑related out‑
comes or indicators of disruption to lactation 
may be related to or influenced by a variety 
of confounding factors such as the overall 
health (or toxicity status) of the maternal 
animal and/or offspring. Toxicokinetic data 
on the test substance and/or its metabolite(s) 
or mode of action data, which might inform 
this issue, are seldom available.
•	When	assessments	of	endocrine	function	
are conducted, they may or may not be 
indicative of adverse MG outcomes, because 
this is critically dependent on the mode or 
mechanism of action of the chemical. This 
information is unknown for many environ‑
mental chemicals.
•	Many	guideline	studies	do	not	evaluate	ani‑
mals that have been exposed during critical 
periods of MG develop  ment. The studies 
that include such exposures are the repro‑
ductive toxicity studies (including the U.S. 
EPA/OECD one‑ and two‑generation stud‑
ies and the NTP RACB study), the U.S. 
EPA peripubertal endocrine assays, the U.S. 
EPA/OECD DNT study, and the perinatal 
phase of the NTP rat carcinogenicity assay.
•	When	the	MG	is	evaluated	histopathologi‑
cally, it is not examined during develop  ment; 
instead, the focus is on adult pathology.
•	In	short-	and	long-term	studies	that	evalu‑
ate general organ toxicity and pathology, 
examination of MG tissue is seldom rou‑
tinely recom  mended for both sexes; there is 
generally a preferential focus on evaluation 
of female MG tissue, even though adverse 
treatment‑related effects could occur in male 
MG tissue.
To address these issues, a paradigm shift 
would be needed for the evaluation of MG 
in guideline studies. Implementing such a 
shift would present a number of challenges. 
These include addressing a) issues of species 
and strain sensitivity; b) the timing of expo‑
sure and assessments; c) the sensitivity of end 
points typically assessed in guideline studies 
for the detection of effects on MG develop‑
ment or function; and d) the statistical power 
of the study design. Treatment‑related effects 
on MG gland develop  ment and/or later life 
consequences, whether structural or func‑
tional and whether transient or permanent, 
should be considered adverse and relevant to 
risk assessment; this approach is consistent 
with U.S. EPA and OECD risk assessment 
guidelines and practice (OECD 2008; U.S. 
EPA 1991, 1996).










Prenatal developmental toxicity a a
Screening developmental/reproduction Xb a a
Two-generation reproduction Xb X X X Xc
RACB Xb X X X Xc
One-generation reproduction Xb X X Xc
Extended one-generation reproduction Xb X X X X
DNT Xb X a a
Uterotrophic assay a a
Hershberger assay Xd a a
Juvenile/pubertal male or female assay X a a
Subacute or subchronic X X Xc
Chronic or carcinogenicity X X X
X indicates that the study includes an assessment of mammary end points.
aRecommended clinical and necropsy evaluations do not focus on palpation or examination of mammary tissue, and 
subsequent histopathology of abnormal MG tissue is not required. bThe study includes a lactation phase, but other 
than the surrogate measurement of pup growth and survival, the guideline does not recommend specific MG end 
points. cExcept for OECD Test Guideline 407 (OECD 2005), which includes routine evaluation of male MG as an indica-
tor of endocrine disruption, MG histopathology is not recommended unless triggered by observed gross abnormalities. 
dAssessment of serum hormone levels (thyroxine, triiodothyronine, testosterone, luteinizing hormone, follicle-stimulating 
hormone) is optional.Mammary gland assessment in guideline studies
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Conclusions
This review and analysis of U.S. EPA, OECD, 
and NTP guidelines for the assessment of 
environ  mental toxicants identified the need to 
expand the focus on MG evaluation in guide‑
line toxicity studies. Several recommendations 
for enhancing MG evaluation in guideline 
toxicology studies have been proposed (Rudel 
et al. 2011). 
First, guidelines should be written or 
revised to more specifically address the exami‑
na  tion of MG end points. Second, considera‑
tion should be given to including the 
histopathological evaluation of MG develop‑
ment in existing or new guideline protocols 
that include offspring treated during in utero 
and postnatal develop  ment and that are 
maintained on study to the age of weaning or 
puberty. The use of a whole‑mount histo‑
pathological technique (described by White 
et al. 2011) is important to this assessment. 
In some studies, such as the DNT study and 
the two‑generation reproduction study, most 
offspring are already committed to other 
assessments. However, two study protocols 
include a develop  mental exposure and that are 
likely to have sufficient dams or pups avail‑
able for MG whole‑mount assessment: the 
U.S. EPA male and female juvenile/pubertal   
assays (where MG could be added to the 
list of tissues collected and assessed at study 
termi  na  tion) and the OECD draft extended 
one‑generation reproduction study [where 
MG could be assessed in parental generation 
dams killed after weaning of the F1 pups, and 
in F1 offspring at specified time points (e.g., 
PND4 after litter standardization, PND 21 
after weaning and discarding extra pups, and 
PND90 at study termination)].
Third, early life exposures should be incor‑
porated into U.S. EPA and OECD rodent 
sub  chronic and carcino  genicity assays, and the 
NTP should consider providing guidance on 
adding peri  natal exposure phases to mouse 
studies, especially because the mouse can be 
a sensitive model for detecting alterations in 
MG morphogenesis after in utero and/or lacta‑
tional exposures and for assessing MG carcino‑
genicity. Finally, consideration should be given 
to enhancing the histo  pathological evaluation 
of male MG tissue, which may be uniquely 
susceptible to develop  mental perturbation or 
risk for breast cancer.
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